Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review
Received: Sep 08, 2024; Accepted: Sep 23, 2024
Published Online: Oct 31, 2024
Abstract
Hepatocellular carcinoma (HCC) remains a critical health concern in Korea, ranking as the second leading cause of cancer mortality and imposing substantial economic burdens, particularly among the working-age population. This review examines recent advancements in treating advanced HCC, referencing the updated 2022 HCC guidelines and the Barcelona Clinical Liver Cancer (BCLC) system. Historically, first-line systemic therapies included sorafenib and lenvatinib, with regorafenib, cabozantinib, or ramucirumab serving as second-line options. Since 2020, immune checkpoint inhibitors have shown superior overall survival than sorafenib, leading to the adoption of combination therapies such as atezolizumab with bevacizumab and durvalumab with tremelimumab as first-line treatments. The IMbrave150 study demonstrated that atezolizumab–bevacizumab significantly extended median overall survival and progression-free survival, with the longest survival reported in any phase 3 trial for advanced HCC. Similarly, the HIMALAYA study indicated that durvalumab combined with tremelimumab significantly improved survival rates. Second-line therapies now include regorafenib, cabozantinib, ramucirumab, nivolumab with ipilimumab, and pembrolizumab, each offering benefits for specific patient populations. Nonetheless, these therapies are associated with side effects that require careful management. Traditional targeted therapies can lead to hypertension, cardiovascular events, and hand-foot skin reactions, whereas immune checkpoint inhibitors may cause immune-related adverse events affecting the skin, gastrointestinal tract, and endocrine system. Clinicians must be well-versed in these treatments and their potential side effects to provide optimal patient care. The emergence of combination therapies targeting complex biological pathways signifies a new paradigm in HCC treatment, emphasizing the importance of continuous education and vigilant monitoring to optimize patient outcomes.
Metrics
QR Code of this Article:
Related Articles
The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review
Ewha Med J 2024;47(4):e58
Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
Ewha Med J 2024;47(4):e65
MRI Findings of Lipiodol Uptake in Hepatocellular Carcinomas: A Focus on Signal Intensity
Ewha Med J 2016;39(4):110-117.
Therapeutic Effect of Transarterial Chemoembolization in Hepatocellular Carcinoma
Ewha Med J 1991;14(1):69-73.
Clinical Studies on 111 Cases of Primary Hepatocellular Carcinoma: The Study for Survival Period and Prognostic Factors
Ewha Med J 1996;19(1):21-30.